Format

Send to

Choose Destination
Trends Biotechnol. 2014 Sep;32(9):456-65. doi: 10.1016/j.tibtech.2014.06.007. Epub 2014 Jul 3.

Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells.

Author information

1
Department of Tumor Immunology, Radboud University Medical Centre and Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
2
Department of Tumor Immunology, Radboud University Medical Centre and Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands. Electronic address: c.figdor@ncmls.ru.nl.

Abstract

Active anti-cancer immune responses depend on efficient presentation of tumor antigens and co-stimulatory signals by antigen-presenting cells (APCs). Therapy with autologous natural APCs is costly and time-consuming and results in variable outcomes in clinical trials. Therefore, development of artificial APCs (aAPCs) has attracted significant interest as an alternative. We discuss the characteristics of various types of acellular aAPCs, and their clinical potential in cancer immunotherapy. The size, shape, and ligand mobility of aAPCs and their presentation of different immunological signals can all have significant effects on cytotoxic T cell activation. Novel optimized aAPCs, combining carefully tuned properties, may lead to efficient immunomodulation and improved clinical responses in cancer immunotherapy.

KEYWORDS:

artificial antigen-presenting cell; cancer; immunotherapy; synthetic dendritic cell

PMID:
24998519
PMCID:
PMC4154451
DOI:
10.1016/j.tibtech.2014.06.007
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center